[ad_1]
Ciaccio, M. & Agnello, L. Biochemical biomarkers alterations in Coronavirus Illness 2019 (COVID-19). Prognosis. 7, 365–372. https://doi.org/10.1515/dx-2020-0057 (2020).
Ciaccio, M. et al. COVID-19 and Alzheimer’s illness. Mind Sci. 11, 305. https://doi.org/10.3390/brainsci11030305 (2021).
Lo Sasso, B. et al. Scientific software of midregional proadrenomedullin in sufferers with COVID-19. Lab. Med. 52, 493–498 (2021).
Olliaro, P. L. An built-in working out of long-term sequelae after acute COVID-19. Lancet Respir. Med. 9, 679–680 (2021).
Bivona, G., Agnello, L. & Ciaccio, M. Biomarkers for analysis and remedy reaction in COVID-19 sufferers. Ann. Lab. Med. 41, 540–548 (2021).
Haas, E. J. et al. Have an effect on and effectiveness of mRNA BNT162b2 vaccine towards SARS-CoV-2 infections and COVID-19 circumstances, hospitalisations, and deaths following a national vaccination marketing campaign in Israel: An observational find out about the use of nationwide surveillance knowledge. Lancet. 397, 1819–1829. https://doi.org/10.1016/S0140-6736(21)00947-8 (2021).
Antonelli, M. et al. Possibility components and illness profile of post-vaccination SARS-CoV-2 an infection in UK customers of the COVID Symptom Learn about app: A potential, community-based, nested, case-control find out about. Lancet Infect. Dis. 22, 43–55 (2022).
Krammer, F. A correlate of coverage for SARS-CoV-2 vaccines is urgently wanted. Nat. Med. 27, 1147–1148 (2021).
Wu, J. et al. SARS-CoV-2 an infection induces sustained humoral immune responses in convalescent sufferers following symptomatic COVID-19. Nat. Commun. 12, 1813. https://doi.org/10.1038/s41467-021-22034-1 (2021).
Wölfel, R. et al. Virological overview of hospitalized sufferers with COVID-2019. Nature 581, 465–469 (2020).
Lo Sasso, B. et al. Analysis of anti-SARS-Cov-2 S-RBD IgG antibodies after COVID-19 mRNA BNT162b2 vaccine. Diagnostics (Basel) 11, 1135 (2021).
Bewley, Ok. R. et al. Quantification of SARS-CoV-2 neutralizing antibody by way of wild-type plaque relief neutralization, microneutralization and pseudotyped virus neutralization assays. Nat. Protoc. 16, 3114–3140 (2021).
Gambino, C. M. et al. Comparability of a speedy immunochromatographic check with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG. Biochem. Med. (Zagreb). 30, 030901 (2020).
Liu, G. & Rusling, J. F. COVID-19 antibody checks and their boundaries. ACS Sens. 6(3), 593–612. https://doi.org/10.1021/acssensors.0c02621 (2021).
Krammer, F. Correlates of coverage from SARS-CoV-2 an infection. Lancet 397, 1421–1423 (2021).
Earle, Ok. A. et al. Proof for antibody as a protecting correlate for COVID-19 vaccines. Vaccine. 39, 4423–4428 (2021).
Khoury, D. S. et al. Neutralizing antibody ranges are extremely predictive of immune coverage from symptomatic SARS-CoV-2 an infection. Nat. Med. 27, 1205–1211 (2021).
Kristiansen, P. A. et al. WHO World Usual for anti-SARS-CoV-2 immunoglobulin. Lancet 397, 1347–1348 (2021).
McMahan, Ok. et al. Correlates of coverage towards SARS-CoV-2 in rhesus macaques. Nature 590, 630–634 (2021).
Brisotto, G. et al. IgG antibodies towards SARS-CoV-2 decay however persist 4 months after vaccination in a cohort of healthcare staff. Clin. Chim. Acta. 523, 476–482 (2021).
Stamatopoulou, M. et al. Speedy decay of anti-SARS-CoV-2 antibodies in infection-naïve healthcare staff 4 months after vaccination. Germs 11, 625–629 (2021).
Malipiero, G., D’Agaro, P., Segat, L., Moratto, A. & Villalta, D. Lengthy-term decay of anti-RBD IgG titers after BNT162b2 vaccination isn’t reflected by way of lack of neutralizing bioactivity towards SARS-CoV-2. Clin. Chim. Acta. 524, 11–17 (2022).
Matusali, G. et al. Differential dynamics of SARS-CoV-2 binding and useful antibodies upon BNT162b2 vaccine: A 6-month follow-up. Viruses 14, 312 (2022).
Padoan, A. et al. Neutralizing antibody titers six months after Comirnaty vaccination: Kinetics and comparability with SARS-CoV-2 immunoassays. Clin. Chem. Lab. Med. https://doi.org/10.1515/cclm-2021-1247 (2021).
Ibarrondo, F. J. et al. Number one, recall, and rot kinetics of SARS-CoV-2 vaccine antibody responses. ACS Nano https://doi.org/10.1021/acsnano.1c03972 (2021).
Bassi, J. et al. Deficient neutralization and speedy decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis sufferers. PLoS One 17, e0263328 (2022).
Gagelmann, N. et al. Antibody reaction after vaccination towards SARS-CoV-2 in adults with haematological malignancies: A scientific overview and meta-analysis. Haematologica https://doi.org/10.3324/haematol.2021.280163 (2021).
Füessl, L. et al. Lowered short- and long-term antibody reaction after SARS-CoV-2 vaccination in hemodialysis sufferers. Vaccines 10, 605 (2022).
Danthu, C. et al. Humoral reaction after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis sufferers and kidney transplant recipients. JASN 32, 2153–2158 (2021).
Eliakim-Raz, N. Antibody Titers ahead of and after a 3rd dose of the SARS-CoV-2 BNT162b2 vaccine in adults elderly ≥60 years. JAMA 326, 2203–2204 (2021).
Gilboa, M. et al. Early Immunogenicity and protection of the 3rd dose of BNT162b2 mRNA Covid-19 vaccine amongst adults older than 60 years; actual global enjoy. J. Infect. Dis. https://doi.org/10.1093/infdis/jiab584 (2021).
Blain, H. et al. Sturdy decay of SARS-CoV-2 spike antibodies after 2 BNT162b2 vaccine doses and prime antibody reaction to a 3rd dose in nursing house citizens. J. Am. Med. Dir. Assoc. 23, 750–753 (2022).
Cucunawangsih, C. et al. Antibody reaction after a 3rd dose mRNA-1273 vaccine amongst vaccinated healthcare staff with two doses of inactivated SARS-CoV-2 vaccine. Int. J. Infect. Dis. 118, 116–118 (2022).
Ducloux, D. et al. Humoral reaction after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in sufferers on hemodialysis. Kidney Int. 100, 702–704 (2021).
Espi, M. et al. A potential observational find out about for justification, protection, and efficacy of a 3rd dose of mRNA vaccine in sufferers receiving upkeep hemodialysis. Kidney Int. 101, 390–402 (2022).
Mair, M. J. et al. 3rd dose of SARS-CoV-2 vaccination in hemato-oncological sufferers and well being care staff: Immune responses and opposed occasions – a retrospective cohort find out about. Eur. J. Most cancers. 165, 184–194 (2022).
Rottenberg, Y. et al. Evaluate of reaction to a 3rd dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in sufferers with cast tumors present process energetic remedy. JAMA Oncol. 8, 300–301 (2022).
Shroff, R. T. et al. Immune responses to 2 and 3 doses of the BNT162b2 mRNA vaccine in adults with cast tumors. Nat. Med. 27, 2002–2011 (2021).
Fenioux, C. et al. SARS-CoV-2 antibody reaction to two or 3 doses of the BNT162b2 vaccine in sufferers handled with anticancer brokers. JAMA Oncol. 8, 612–617 (2022).
Bar-On, Y. M. et al. Coverage of BNT162b2 vaccine booster towards Covid-19 in Israel. N. Engl. J. Med. 385, 1393–1400 (2021).
[ad_2]
Discussion about this post